These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 39079344

  • 1. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon α-accelerated murine lupus.
    Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S.
    Int Immunopharmacol; 2024 Oct 25; 140():112692. PubMed ID: 39079344
    [Abstract] [Full Text] [Related]

  • 2. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C.
    Clin Immunol; 2018 Dec 25; 197():205-218. PubMed ID: 30339790
    [Abstract] [Full Text] [Related]

  • 3. IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice.
    Liu Z, Bethunaickan R, Huang W, Ramanujam M, Madaio MP, Davidson A.
    J Immunol; 2011 Aug 01; 187(3):1506-13. PubMed ID: 21705616
    [Abstract] [Full Text] [Related]

  • 4. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.
    Katewa A, Wang Y, Hackney JA, Huang T, Suto E, Ramamoorthi N, Austin CD, Bremer M, Chen JZ, Crawford JJ, Currie KS, Blomgren P, DeVoss J, DiPaolo JA, Hau J, Johnson A, Lesch J, DeForge LE, Lin Z, Liimatta M, Lubach JW, McVay S, Modrusan Z, Nguyen A, Poon C, Wang J, Liu L, Lee WP, Wong H, Young WB, Townsend MJ, Reif K.
    JCI Insight; 2017 Apr 06; 2(7):e90111. PubMed ID: 28405610
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
    Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH.
    Arthritis Rheum; 2012 Feb 06; 64(2):493-503. PubMed ID: 21905015
    [Abstract] [Full Text] [Related]

  • 7. Tuftsin-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model.
    Shemer A, Kivity S, Shovman O, Bashi T, Perry O, Watad A, Ben-Ami Shor D, Volkov A, Barshack I, Bragazzi NL, Krule A, Fridkin M, Amital H, Blank M, Shoenfeld Y.
    Clin Exp Immunol; 2018 Aug 06; 193(2):160-166. PubMed ID: 29698559
    [Abstract] [Full Text] [Related]

  • 8. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Zhang Z, Oyesanya RA, Campbell DJ, Almenara JA, Dewitt JL, Sirica AE.
    Hepatology; 2010 Sep 06; 52(3):975-86. PubMed ID: 20607690
    [Abstract] [Full Text] [Related]

  • 9. Interferon alpha on NZM2328.Lc1R27: enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failure.
    Dai C, Wang H, Sung SS, Sharma R, Kannapell C, Han W, Wang Q, Davidson A, Gaskin F, Fu SM.
    Clin Immunol; 2014 Sep 06; 154(1):66-71. PubMed ID: 24981059
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.
    Liao W, Zheng H, Wu S, Zhang Y, Wang W, Zhang Z, Zhou C, Wu H, Min J.
    Am J Nephrol; 2017 Sep 06; 46(5):371-379. PubMed ID: 29069649
    [Abstract] [Full Text] [Related]

  • 12. B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.
    Jacob N, Guo S, Mathian A, Koss MN, Gindea S, Putterman C, Jacob CO, Stohl W.
    J Immunol; 2011 Apr 15; 186(8):4984-93. PubMed ID: 21383240
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of tissue injury in lupus nephritis.
    Nowling TK, Gilkeson GS.
    Arthritis Res Ther; 2011 Apr 15; 13(6):250. PubMed ID: 22192660
    [Abstract] [Full Text] [Related]

  • 14. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H, Li T, Chen S, Gu Y, Ye S.
    Arthritis Rheumatol; 2015 Dec 15; 67(12):3190-200. PubMed ID: 26245802
    [Abstract] [Full Text] [Related]

  • 15. Reversible SAHH inhibitor protects against glomerulonephritis in lupus-prone mice by downregulating renal α-actinin-4 expression and stabilizing integrin-cytoskeleton linkage.
    He S, Liu X, Lin Z, Liu Y, Gu L, Zhou H, Tang W, Zuo J.
    Arthritis Res Ther; 2019 Jan 29; 21(1):40. PubMed ID: 30696480
    [Abstract] [Full Text] [Related]

  • 16. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
    Benter IF, Sarkhou F, Al-Khaldi AT, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH, Akhtar S.
    J Drug Target; 2015 Jan 29; 23(6):506-18. PubMed ID: 26114862
    [Abstract] [Full Text] [Related]

  • 17. Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.
    Yuan Y, Kasar S, Underbayev C, Vollenweider D, Salerno E, Kotenko SV, Raveche E.
    Mol Immunol; 2012 Sep 29; 52(2):61-70. PubMed ID: 22578383
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
    Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M, Fujita M.
    Cancer Sci; 2009 Aug 29; 100(8):1526-31. PubMed ID: 19459856
    [Abstract] [Full Text] [Related]

  • 19. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A.
    Neoplasia; 2012 Feb 29; 14(2):121-30. PubMed ID: 22431920
    [Abstract] [Full Text] [Related]

  • 20. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
    Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF, Hudson-Curtis BL, Gilmer TM.
    Cell Prolif; 2007 Aug 29; 40(4):580-94. PubMed ID: 17635524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.